Amneal Pharmaceuticals, Inc. (FRA:2DT)

Germany flag Germany · Delayed Price · Currency is EUR
10.50
+0.10 (0.96%)
Last updated: Dec 1, 2025, 3:29 PM CET
41.89%
Market Cap3.39B
Revenue (ttm)2.50B
Net Income (ttm)5.03M
Shares Outn/a
EPS (ttm)0.01
PE Ratio674.99
Forward PE14.40
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume8
Open10.60
Previous Close10.40
Day's Range10.50 - 10.60
52-Week Range5.70 - 11.10
Betan/a
RSI66.48
Earnings DateMar 6, 2026

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalm... [Read more]

Industry Pharmaceutical Preparations
Founded 2002
Employees 8,300
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 2DT
Full Company Profile

Financial Performance

In 2024, Amneal Pharmaceuticals's revenue was $2.79 billion, an increase of 16.73% compared to the previous year's $2.39 billion. Losses were -$116.89 million, 39.2% more than in 2023.

Financial numbers in USD Financial Statements

News

There is no news available yet.